Cite

    Singh, N. et al. (2022). Comparison of the efficacy and cost‐effectiveness of an immunologically targeted low‐dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus. Clinical and experimental dermatology. pp. 1508-1516. [Online].